



(51) International Patent Classification:

C12N 15/113 (2010.01) C07H 21/00 (2006.01)
A61K 31/7125 (2006.01) C12N 15/19 (2006.01)
A61P 11/00 (2006.01) C12N 15/55 (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:

PCT/CA2012/000169

(22) International Filing Date:

23 February 2012 (23.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/446,144 24 February 2011 (24.02.2011) US

(71) Applicant (for all designated States except US):
PHARMAXIS LTD [AU/AU]; 20 Rodborough Road,
Frenchs Forest, New South Wales 2086 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SEGUIN, Rosanne**
[CA/CA]; Apt #205, 4119 rue Ontario Est, Montreal,
Québec H1V 1J7 (CA). **FERRARI, Nicolay** [CA/CA];
174 Denis-Veronneau, Boucherville, Québec J4B 8L8
(CA).

(74) Agents: **NORTON ROSE CANADA LLP/S.E.N.C.R.L.,**
s.r.l. et al.; 1 Place Ville Marie, Suite 2500, Montreal,
Québec H3B 1R1 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: OLIGONUCLEOTIDE INHIBITORS WITH CHIMERIC BACKBONE AND 2-AMINO-2'-DEOXYADENOSINE

Figure 20:



(57) Abstract: There is provided herein, an oligonucleotide directed against a target gene, wherein the oligonucleotide is capable of hybridizing to at least a portion of a nucleic acid sequence encoding the gene under stringent conditions, and wherein, at least one nucleotide of the oligonucleotide is 2-amino-2'- deoxyadenosine (DAP); and the internucleoside linkages of the oligonucleotide comprises at least three alternating segments, each segment consisting of either at least one phosphorothioate or at least one phosphodiester bond.